publication venue for
- Correction: The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.. 74:-. 2024
- The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer.. 73:-. 2024
- Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53.. 73:-. 2024
- Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.. 72:-. 2023
- A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.. 72:2267-2282. 2023
- Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.. 72:2067-2074. 2023
- Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.. 72:2005-2013. 2023
- Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.. 72:1727-1735. 2023
- Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival.. 71:1157-1165. 2021
- Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.. 70:2761-2769. 2021
- Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.. 69:2403-2408. 2020
- An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.. 68:849-859. 2018
- Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.. 67:1833-1844. 2018
- Intratumoral immunocytokine treatment results in enhanced antitumor effects.. 57:1891-902. 2008